Hong Kong-listed Metis TechBio has signed a collaboration with Eli Lilly worth up to US$1.1 billion to develop tissue-specific drug-delivery technologies using its AI-driven platform. Metis will receive an upfront payment and milestone fees, plus tiered royalties on net sales of resulting products.
This article provides a practical protocol for testing Replai, an AI email assistant, on routine replies, difficult refusals and multilingual messages, assessing tone, invented commitments, privacy and the need for final human approval.
